RGEN · Repligen Corporation · Stock research

TXG

10x Genomics, Inc.

First lower close of the run: 2026-08-24 at $63.80, 2.0% under the 2026-08-21 record close of $65.12, with price still above every published target (high mark Stephens $65, 08-12; 16-analyst average $49.54). No company item since the 08-06 Q2 print and no rating action in twelve sessions, so the leg runs on a news vacuum until the ~09-09 short-interest file, with no company checkpoint before ~2026-11-05.

BFLY

Butterfly Network, Inc.

Butterfly Embedded chip-licensing story got marquee validation — Midjourney's up-to-$74M/5yr full-body scanner on 40 Ultrasound-on-Chip modules (2026-06-18) plus 2nd partner Aleph Neuro (2026-06-25). Fundamentals still accelerating, but the June double has stalled and news thinned; a binary Q2 print (~early Aug) is now the next input and the easy momentum leg is spent.

PSNL

Personalis, Inc.

The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus two other suitors. Price broke to a $16.39 52-week high; Needham $17 and TD Cowen $18 now sit above the tape. Aug-4 Q2 is the next hard date.

ABT

Abbott Laboratories

De-rating unwind is now largely priced: $82.56 close on 2026-05-11 to $111.25 on 2026-08-14, RSI 72.2, with the 2026-08-11 Google Health/Lingo partnership and Wolfe's 2026-08-13 upgrade to $130 as the newest fuel. Nothing tests the 6.5%–7.5% FY comparable guide against Q2's 4.8% until the ~mid-October Q3 print; ESC Munich on 2026-08-28 is the only dated event inside 30 days.